专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017116569A1 METHODS FOR TREATING DIABETES 审中-公开
标题翻译：治疗糖尿病的方法
公开(公告)号：WO2017116569A1
公开(公告)日：2017-07-06
申请号：PCT/US2016/061403
申请日：2016-11-10
申请人： CITY OF HOPE
发明人： ZENG, Defu
IPC分类号： A61K35/28 , A61K39/39 , A61K35/39 , A61P3/10
CPC分类号： A61K35/39 , A01K2267/0325 , A61K31/00 , A61K35/28 , A61K38/1808 , A61K38/2207 , C12N5/0676 , A61K2300/00
摘要： Disclosed herein are methods for treating type 1 diabetes by reversing autoimmunity and replenishing beta cells. More specifically, type 1 diabetes is treated by administering exogenous Sox9+ cells and a low dose of gastrin and epidermal growth factor (GE) under hyperglycemia or medium hyperglycemia condition during or after induction of mixed chimerism in a subject.
摘要翻译：本文公开了通过逆转自身免疫和补充β细胞来治疗1型糖尿病的方法。更具体地，通过在受试者中诱导混合嵌合体期间或之后，在高血糖症或中等高血糖症状况下施用外源性Sox9 +细胞和低剂量胃泌素和表皮生长因子（GE）来治疗1型糖尿病。

2. 发明申请

WO2022040210A1 HAPLOIDENTICAL MIXED CHIMERISM FOR TREATING AUTOIMMUNE DISEASES 审中-公开
公开(公告)号：WO2022040210A1
公开(公告)日：2022-02-24
申请号：PCT/US2021/046339
申请日：2021-08-17
申请人： CITY OF HOPE
发明人： ZENG, Defu
IPC分类号： A61K31/675 , A61K31/7056 , A61K35/14 , A61K35/17 , A61K35/26 , A61K35/28
摘要： Disclosed are methods of treating or preventing autoimmune diseases by inducing haploidentical mixed chimerism and condition regimen for by inducing haploidentical mixed chimerism.

3. 发明申请

WO2019071029A1 PREVENTION AND TREATMENT OF GVHD AND AUTOIMMUNE DISEASES 审中-公开
公开(公告)号：WO2019071029A1
公开(公告)日：2019-04-11
申请号：PCT/US2018/054446
申请日：2018-10-04
申请人： CITY OF HOPE
发明人： ZENG, Defu , RIGGS, Arthur
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , A61P37/06 , C07K2317/76
摘要： Disclosed herein are methods of preventing and treating GVHD and autoimmune diseases. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a subject to in vivo knock down Stat3 in the T cells and/or B cells of the subject. Alternatively, the methods entail contacting donor T cells and/or B cells with an effective amount of a therapeutic agent to in vitro knock down Stat3 and administering the Stat3-deficient T cells and/or B cells to the subject. Some examples of the therapeutic agent include small molecule Stat3 inhibitors such as Stat3 siRNAs delivered by an antibody to specifically knock down Stat3 in the lymphocytes of the target tissue.

4. 发明申请

WO2022147509A1 PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD) 审中-公开
公开(公告)号：WO2022147509A1
公开(公告)日：2022-07-07
申请号：PCT/US2022/011051
申请日：2022-01-03
申请人： CITY OF HOPE
发明人： ZENG, Defu , SONG, Qingxiao , RIGGS, Arthur, D.
IPC分类号： A61K39/00 , A61K39/395 , A61P1/00 , A61P37/06 , C07K16/24
摘要： Disclosed is a method of preventing or treating acute GVHD (aGVHD) such as gut aGVHD, steroid-resistant aGVHD, and steroid-resistant gut aGVHD in a subject receiving a hematopoietic cell transplantation (HCT) or autoimmune colitis by administering to the subject an effective amount of an anti-IL-22 antibody, an anti-IL-6 antibody, donor-type CX3CR1hi MNPs, donor-type NK cells, a ceacam-1 antagonist, an anti-Gr-1 antibody, or a combination thereof.

5. 发明申请

WO2022119931A1 PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) 审中-公开
公开(公告)号：WO2022119931A1
公开(公告)日：2022-06-09
申请号：PCT/US2021/061421
申请日：2021-12-01
申请人： CITY OF HOPE
发明人： ZENG, Defu , RIGGS, Arthur, D. , SONG, Qingxiao
IPC分类号： A61K39/00 , A61K39/395 , A61P29/00 , C07K16/24
摘要： Disclosed is a method of preventing or treating GVHD while preserving GVL activity in a subject receiving a hematopoietic cell transplantation (HCT) by administering to the subject an effective amount of an anti-IL-2 antibody such as an anti-IL-2-JES6 antibody.

6. 发明申请

WO2018156955A1 METHODS FOR IN VIVO EXPANSION OF CD8+ T CELLS AND PREVENTION OR TREATMENT OF GVHD 审中-公开
公开(公告)号：WO2018156955A1
公开(公告)日：2018-08-30
申请号：PCT/US2018/019524
申请日：2018-02-23
申请人： CITY OF HOPE
发明人： ZENG, Defu
IPC分类号： A61K35/28 , A61K39/00
摘要： Disclosed herein are methods of preventing and treating acute GVHD and chronic GVHD after hematopoietic cell transplantation (HCT), as well as methods of in vivo augmenting expansion of donor CD8+ T cells in the lymphoid tissues in vivo after HCT and methods of augmenting recipient tissue expression of programmed death-ligand 1 (PD-L1, or B7H1) after HCT. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a recipient simultaneously, immediately before, or immediately after HCT to temporarily deplete CD4+ T cells or to reduce serum IL-2. Some examples include an anti-CD4 antibody or an anti-CD4-meditope-immunotoxin, an anti-IL-2 antibody, an agent blocking IL-2R, and/or a PD-L1-Ig. One or more additional therapeutic agents such as IFN-y can be administered.

7. 发明申请

WO2017083555A1 CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISM 审中-公开
标题翻译：诱导混合燃烧的调节方法和方法
公开(公告)号：WO2017083555A1
公开(公告)日：2017-05-18
申请号：PCT/US2016/061382
申请日：2016-11-10
申请人： CITY OF HOPE
发明人： ZENG, Defu
IPC分类号： A61K39/395 , A61K35/28 , A61P3/10 , A61P37/06 , C07K16/28
CPC分类号： A61K35/28 , A01K67/027 , A61K31/00
摘要： Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4 + T-depleted spleen cells, donor CD8 + T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.
摘要翻译：本发明公开了通过用无辐射，低剂量的环磷酰胺（CY），喷司他丁（PT）和抗球蛋白磷酸酯酶抑制剂（PT）调理受体来诱导MHC或HLA错配的混合嵌合体的调理方案和方法胸腺细胞球蛋白（ATG）移植供体骨髓细胞之前。在某些实施方案中，供体骨髓细胞可以是CD4 + T耗尽的骨髓细胞。调理方案和方法还可以包括施用选自供体CD4 + T耗尽的脾细胞，供体CD8 + T细胞和供体的调节供体细胞的一个或多个群体 G-CSF动员的外周血单核细胞。预处理方案在临床上是可以接受的，可用于治疗遗传性血液病和自身免疫性疾病，以及促进器官移植免疫耐受。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式